Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 10/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 9/20 | 1.00 |
| ▸ | TUBB | P07437 | 9/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 9/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 9/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 9/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 9/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 9/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 9/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 9/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 9/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 9/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 9/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 9/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 9/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Combretastatin SCHEMBL19955 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL30334938 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL5566666 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL29394501 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL19956 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6429578 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6430099 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6430650 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6429581 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6429821 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048022-A1 | ENDOTHELIAL DAMAGE AND NANOPARTICLE TARGETING: COMPOSITIONS, PROCESSES, USES | NANOPROBES INC (US) | 2026-02-19 | — | — | US | claimed |
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | claimed |
| EP-4525834-A1 | ENDOTHELIAL DAMAGE AND NANOPARTICLE TARGETING: COMPOSITIONS, PROCESSES, USES | Nanoprobes, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| CN-118845653-A | PH response type polylysine derivative nano micelle carrier and preparation method and application thereof | 安徽中医药大学 | 2024-10-29 | — | — | CN | claimed |
| CN-118576550-A | Calcium carbonate nanoparticle with tumor immune suppression reversing microenvironment and preparation method and application thereof | 广州医科大学 | 2024-09-03 | — | — | CN | claimed |
| US-20240285971-A1 | Intratumoral Alpha-Emitter Radiation in Combination with Vasculature Inhibitors | ALPHA TAU MEDICAL LTD. (IL) | 2024-08-29 | — | — | US | claimed |
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-06-27 | — | — | US | claimed |
| US-20240156965-A1 | DICHALCOGENIDE PRODRUGS | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-05-16 | — | — | US | claimed |
| EP-4359071-A1 | INTRATUMORAL ALPHA-EMITTER RADIATION IN COMBINATION WITH VASCULATURE INHIBITORS | Alpha Tau Medical Ltd. (IL) | 2024-05-01 | — | — | EP | claimed |
| US-20240130982-A1 | TREATMENT OF AVASCULAR OR HYPOVASCULAR MICRO-TUMORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-04-25 | — | — | US | claimed |
| CN-117056966-A | System for analyzing consistency of applet privacy policy and authority call | 西安电子科技大学 | 2023-11-14 | — | — | CN | claimed |
| WO-2022269445-A1 | INTRATUMORAL ALPHA-EMITTER RADIATION IN COMBINATION WITH VASCULATURE INHIBITORS | ALPHA TAU MEDICAL LTD. (IL) | 2022-12-29 | — | — | WO | claimed |
| CN-111603436-B | Photodynamic silica nanomaterial @ hydrogel composite drug loading system, and preparation method and application thereof | 徐州医科大学 | 2022-12-27 | — | — | CN | claimed |
| US-20220401556-A1 | USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORS | ONCOTELIC THERAPEUTICS, INC. | 2022-12-22 | — | — | US | claimed |
| WO-2022214598-A1 | DICHALCOGENIDE PRODRUGS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2022-10-13 | — | — | WO | claimed |
| EP-4071148-A1 | DICHALCOGENIDE PRODRUGS | Ludwig-Maximilians-Universität München (DE) | 2022-10-12 | — | — | EP | claimed |
| WO-2022200347-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2022-09-29 | — | — | WO | claimed |
| EP-4062942-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | Ludwig-Maximilians-Universität München (DE) | 2022-09-28 | — | — | EP | claimed |
| US-11419934-B2 | Use of VDAS to enhance immunomodulating therapies against tumors | ONCOTELIC THERAPEUTICS, INC. (US) | 2022-08-23 | — | — | US | claimed |
| CN-110672745-B | Method for measuring combretastatin and metabolites thereof | 复旦大学附属肿瘤医院 | 2022-03-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048022-A1 | ENDOTHELIAL DAMAGE AND NANOPARTICLE TARGETING: COMPOSITIONS, PROCESSES, USES | VEGFA, FLT1, FLT4 | TUBB1 904/4885TUBB4A 948/4885TUBB 1057/4885 |
| US-20220401556-A1 | USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORS | CD274, PDCD1LG2, PDCD1 | TUBB1 3110/4885TUBB4A 1043/4885TUBB 3743/4885 |
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | CBS, MSR1, P4HB | TUBB1 2263/4885TUBB4A 2646/4885TUBB 2338/4885 |
| US-20240156965-A1 | DICHALCOGENIDE PRODRUGS | DHCR7, DECR1, CYP27A1 | TUBB1 3482/4885TUBB4A 2635/4885TUBB 3289/4885 |
| US-11419934-B2 | Use of VDAS to enhance immunomodulating therapies against tumors | CD274, PDCD1LG2, CA4 | TUBB1 2952/4885TUBB4A 999/4885TUBB 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.